Brainstorm Cell Therapeutics Revenue
Biotechnology Research • 
Petah Tikva, Center District, Israel • 21-50 Employees
Brainstorm Cell Therapeutics revenue & valuation
| Annual revenue | $1,000,000 |
| Revenue per employee | $32,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $3,200,000 |
| Total funding | $11,500,000 |
Key Contacts at Brainstorm Cell Therapeutics
Uri Yablonka
Executive Director & Evp, Chief Business Officer
Chaim Lebovits
Chief Executive Officer
Company overview
| Headquarters | 12 Bazel Street, POB 10019, Kiryat Aryeh, Petach Tikva 49001, IL |
| Phone number | +9722014880460 |
| Website | |
| NAICS | 541714 |
| SIC | 873 |
| Keywords | Drug Development, ALS, Neurodegenerative Diseases, Stem Cell Therapy |
| Founded | 2004 |
| Employees | 21-50 |
| Socials |
Brainstorm Cell Therapeutics Email Formats
Brainstorm Cell Therapeutics uses 5 email formats. The most common is {first initial}{last name} (e.g., jdoe@brainstorm-cell.com), used 29% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@brainstorm-cell.com | 35.5% |
{first name}{last name} | johndoe@brainstorm-cell.com | 29% |
{first initial}.{last name} | j.doe@brainstorm-cell.com | 25.8% |
{first name} | john@brainstorm-cell.com | 6.5% |
About Brainstorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc. (NASDAQ) develops autologous stem cell therapies for neurodegenerative disorders such as ALS, MS, and Parkinson’s disease. These diseases have limited treatment options and represent unmet medical needs. NurOwn® is BrainStorm’s proprietary process for differentiating autologous mesenchymal stem cells (MSC) into neurotrophic factor (NTF)-secreting cells, transplanted at or near the affected tissue site. Our technology converts MSCs into a living drug delivery system for NTFs. We have proof-of-concept in various animal models of neurodegenerative diseases, including Parkinson's, Huntington's, ALS, MS, and peripheral nerve injury. We have completed two single-arm clinical trials in ALS patients in Israel, demonstrating good safety and tolerability profiles and strong efficacy signals. We also finalized a Phase 3 randomized, double-blind, placebo-controlled clinical trial at multiple US sites, supported by a $16 million USD grant from the California Institute for Regenerative Medicine (CIRM) and another grant from the ALS Association. Currently, we are planning a Phase 3b clinical trial of NurOwn® in ALS under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). For more information, visit www.brainstorm-cell.com
Employees by Management Level
Total employees: 21-50
Seniority
Employees
Employees by Department
Brainstorm Cell Therapeutics has 19 employees across 8 departments.
Departments
Number of employees
Funding Data
Explore Brainstorm Cell Therapeutics's funding history, including investment rounds, total capital raised, and key backers.
Brainstorm Cell Therapeutics Tech Stack
Discover the technologies and tools that power Brainstorm Cell Therapeutics's digital infrastructure, from frameworks to analytics platforms.
Security
WordPress plugins
WordPress themes
JavaScript libraries
WordPress plugins
Video players
JavaScript libraries
JavaScript libraries
Miscellaneous
Page builders
JavaScript libraries
Spain
Guernsey
United Kingdom
Russian Federation
Frequently asked questions
4.8
40,000 users
